ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Harmony Biosciences Enrolls First Patient in Pitolisant Trial for Excessive Daytime Sleepiness
December 17, 2020Harmony Biosciences announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome.
Pharma Sources Insight January 2025
